BioPharmSignal logoBioPharmSignal

Biotech News

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals (TERN)Terns PharmaceuticalsCompany update

FOSTER CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of April 1, 2026 equity inducement awards to three new employees under the terms of the 2022

Open original release

Related news

ZNTLZentalis2026-06-01 21:00 EST

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GERNGeron2026-07-22 20:01 EST

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAMSNewAmsterdam Pharma2026-07-02 20:01 EST

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IDYAIDEAYA Biosciences2026-06-26 10:00 EST

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

MLYSMineralys Therapeutics2026-07-27 20:01 EST

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GERNGeron2026-07-14 20:26 EST

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

BMYBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

RVMDRevolution Medicines2026-05-06 22:00 EST

Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer

View all latest news

Terns Pharmaceuticals

Terns Pharmaceuticals is a small-molecule biotech focused on oncology and metabolic disease opportunities. Its pipeline is built around targeted therapies with room for multiple shots on goal.

Recent company news

TERNTerns Pharmaceuticals2026-04-27 12:05 EST

Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia

TERNTerns Pharmaceuticals2026-04-02 20:05 EST

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

TERNTerns Pharmaceuticals2026-03-25 10:48 EST

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

TERNTerns Pharmaceuticals2026-02-25 21:05 EST

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

TERNTerns Pharmaceuticals2026-01-07 21:05 EST

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Stock data

Close
52.95 USD
Market cap
6.12B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States